PE20120581A1 - Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina - Google Patents

Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina

Info

Publication number
PE20120581A1
PE20120581A1 PE2011001455A PE2011001455A PE20120581A1 PE 20120581 A1 PE20120581 A1 PE 20120581A1 PE 2011001455 A PE2011001455 A PE 2011001455A PE 2011001455 A PE2011001455 A PE 2011001455A PE 20120581 A1 PE20120581 A1 PE 20120581A1
Authority
PE
Peru
Prior art keywords
lactama
alkyl
renin inhibitors
intermediaries
synthesis
Prior art date
Application number
PE2011001455A
Other languages
English (en)
Inventor
Gottfried Sedelmeier
Dominique Grimler
Acemoglu Murat
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120581(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120581A1 publication Critical patent/PE20120581A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA A UN PROCESO PARA PREPARACION DE FORMULA XIV, DONDE R3 ES ALQUILO C1-C7, CICLOALQUILO C3-C8; R4 ES ALQUILO C1-C7, ALQUENILO C2-C7, CICLOALQUILO C3-C8, ENTRE OTROS; R1 ES HALOGENO, HIDROXILO, HALOGENOALQUILO C1-C6, (ALCOXI C1-C6)-(ALQUILOXI C1-C6), ENTRE OTROS; R2 ES HALOGENO, HIDROXILO, ALQUILO C1-C4, ALCOXI C1-C4. DICHO PROCESO COMPRENDE: A) LA FABRICACION Y ACTIVACION DE UN COMPUESTO DE FORMULA VI, DONDE Act ES UN GRUPO ACTIVADOR DE PREFERENCIA CARBAMATO; B) ABERTURA DEL ANILLO LACTAMA CON UN DERIVADO FENILO; C) REDUCCION DEL CARBONILO BENCILICO Y D) HACER REACCIONAR EL COMPUESTO OBTENIDO CON UN DERIVADO DE AMINA Y REMOVER EL GRUPO ACTIVADOR Act PARA OBTENER EL COMPUESTO XIV. DICHO PROCESO PROPORCIONA UNA RUTA SINTETICA ALTERNATIVA PARA ASEGURAR SU ELABORACION DE UNA MANERA SIMPLE Y EFICIENTE, SIENDO UTIL COMO INHIBIDORES DE RENINA
PE2011001455A 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina PE20120581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0521083.6A GB0521083D0 (en) 2005-10-17 2005-10-17 Organic compounds

Publications (1)

Publication Number Publication Date
PE20120581A1 true PE20120581A1 (es) 2012-06-08

Family

ID=35451886

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2006001252A PE20070792A1 (es) 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina
PE2011001455A PE20120581A1 (es) 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2006001252A PE20070792A1 (es) 2005-10-17 2006-10-16 Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina

Country Status (30)

Country Link
US (2) US7772405B2 (es)
EP (1) EP1948643B1 (es)
JP (3) JP5356031B2 (es)
KR (1) KR101294432B1 (es)
CN (2) CN101111493B (es)
AR (1) AR058089A1 (es)
AU (1) AU2006303489B2 (es)
BR (1) BRPI0617492A2 (es)
CA (2) CA2625034C (es)
CY (1) CY1114308T1 (es)
DK (1) DK1948643T3 (es)
EC (1) ECSP088368A (es)
ES (1) ES2427098T3 (es)
GB (1) GB0521083D0 (es)
HK (1) HK1120509A1 (es)
HR (1) HRP20130793T1 (es)
IL (1) IL190330A (es)
JO (1) JO2926B1 (es)
MY (1) MY145466A (es)
NO (1) NO342854B1 (es)
NZ (1) NZ567042A (es)
PE (2) PE20070792A1 (es)
PL (1) PL1948643T3 (es)
PT (1) PT1948643E (es)
RU (1) RU2432354C2 (es)
SI (1) SI1948643T1 (es)
TN (1) TNSN08170A1 (es)
TW (1) TWI395733B (es)
WO (1) WO2007045420A2 (es)
ZA (1) ZA200802632B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds
DE102005052195A1 (de) 2005-10-28 2007-05-03 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von chiralen Octensäurederivaten
MX2009010699A (es) * 2007-04-03 2010-03-10 Novartis Ag Nuevos metodos.
EP2173698A2 (en) * 2007-06-19 2010-04-14 Novartis Ag Process for the synthesis of intermediates of renin inhibitors such as aliskiren
DE102007049039A1 (de) * 2007-10-11 2009-04-16 Reuter Chemischer Apparatebau Kg Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
SI2189442T1 (sl) * 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
US8779198B2 (en) 2009-08-11 2014-07-15 Novartis Ag Ring opening of lactones and lactams
WO2011051853A1 (en) * 2009-10-29 2011-05-05 CarboDesign LLC Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
US20110137047A1 (en) * 2009-12-07 2011-06-09 CarboDesign LLC Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
CN101774986B (zh) 2010-01-06 2012-03-28 浙江天宇药业股份有限公司 一种制备阿利克伦及其中间体的方法
CN102241650B (zh) * 2010-05-14 2014-05-07 浙江九洲药业股份有限公司 用于制备阿立克仑的中间体化合物及相关制备方法
CN102485722B (zh) * 2010-12-06 2014-05-07 博瑞生物医药技术(苏州)有限公司 阿利克仑、其中间体和药用盐及制备方法
CN102775393B (zh) * 2011-05-09 2014-08-27 上海现代制药股份有限公司 一种药物中间体的制备方法
US8703976B2 (en) 2011-10-02 2014-04-22 Milan Soukup Manufacturing process for 8-aryloctanoic acids such as Aliskiren
CN102746182B (zh) * 2012-07-27 2014-09-03 浙江普洛医药科技有限公司 一种阿利克伦的制备方法
CN103059012B (zh) * 2013-01-30 2016-06-22 浙江海翔药业股份有限公司 1,8-二羰基-4,5-环氧化合物及其制备方法
CN106220528B (zh) * 2014-02-28 2018-05-08 华润双鹤药业股份有限公司 阿利吉仑的4-位差向异构体、其制备方法及用途
CN105294612A (zh) * 2014-06-05 2016-02-03 山东威智医药工业有限公司 阿利克仑中间体及其制备方法和应用
US10087190B1 (en) * 2017-04-24 2018-10-02 Purdue Research Foundation Lactones
CN114315749B (zh) * 2021-12-13 2024-04-26 湖南华腾医药有限公司 一种连续流微反应器合成阿利克仑中间体的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
AU5518500A (en) * 1999-07-29 2001-02-19 Speedel Pharma Ag 2-alkyl-5-halogen-pent-4-ene carboxylic acids and their production
FR2801051B1 (fr) * 1999-11-17 2001-12-14 Adir Nouveaux composes aminopyrroline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6310904B1 (en) 2000-05-31 2001-10-30 Honeywell International, Inc. Measurement method to facilitate production of self-aligning laser gyroscope block
ES2274847T3 (es) 2000-12-14 2007-06-01 Speedel Pharma Ag Proceso para preparar ariloctanoil-amidas.
US7164031B2 (en) * 2001-09-07 2007-01-16 Basf Aktiengesellschaft Method for the production of 2-pyrrolidone
GB0212410D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Organic compounds
CN102260188A (zh) * 2003-11-26 2011-11-30 诺瓦提斯公司 有机化合物
KR20070001922A (ko) * 2003-12-12 2007-01-04 와이어쓰 심장혈관질환 치료에 유용한 퀴놀린
EP1712548A3 (en) * 2004-03-19 2006-11-02 Speedel Experimenta AG 5-amino-4-hydroxy-7-(pyridinylmethyl)-alkanamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
EP1582523A1 (en) * 2004-04-02 2005-10-05 Ludwig-Maximilians-Universität München Method of preparing organomagnesium compounds
GB0419361D0 (en) 2004-08-31 2004-10-06 Novartis Ag Organic compounds
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
GB0521083D0 (en) * 2005-10-17 2005-11-23 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR058089A1 (es) 2008-01-23
IL190330A (en) 2013-12-31
CA2625034A1 (en) 2007-04-26
TWI395733B (zh) 2013-05-11
CN103121995B (zh) 2016-08-03
CA2625034C (en) 2014-08-19
KR20080057285A (ko) 2008-06-24
PL1948643T3 (pl) 2013-11-29
JO2926B1 (en) 2015-09-15
US20080262246A1 (en) 2008-10-23
ZA200802632B (en) 2009-04-29
CY1114308T1 (el) 2016-08-31
TW200800965A (en) 2008-01-01
EP1948643A2 (en) 2008-07-30
JP5792139B2 (ja) 2015-10-07
US20100267965A1 (en) 2010-10-21
US7772405B2 (en) 2010-08-10
JP2014196312A (ja) 2014-10-16
AU2006303489B2 (en) 2011-04-07
JP2009514808A (ja) 2009-04-09
CN103121995A (zh) 2013-05-29
RU2008119276A (ru) 2009-11-27
PE20070792A1 (es) 2007-09-10
CA2829487A1 (en) 2007-04-26
ECSP088368A (es) 2008-05-30
WO2007045420A2 (en) 2007-04-26
ES2427098T3 (es) 2013-10-28
NO20082263L (no) 2008-07-07
IL190330A0 (en) 2009-09-22
CN101111493B (zh) 2013-02-13
BRPI0617492A2 (pt) 2011-07-26
TNSN08170A1 (en) 2009-10-30
PT1948643E (pt) 2013-09-05
MY145466A (en) 2012-02-15
EP1948643B1 (en) 2013-06-05
GB0521083D0 (en) 2005-11-23
DK1948643T3 (da) 2013-09-08
KR101294432B1 (ko) 2013-08-07
SI1948643T1 (sl) 2013-10-30
WO2007045420A3 (en) 2007-06-07
HK1120509A1 (en) 2009-04-03
JP5356031B2 (ja) 2013-12-04
RU2432354C2 (ru) 2011-10-27
JP2013032369A (ja) 2013-02-14
CN101111493A (zh) 2008-01-23
NZ567042A (en) 2012-02-24
US8198465B2 (en) 2012-06-12
HRP20130793T1 (hr) 2013-09-30
AU2006303489A1 (en) 2007-04-26
NO342854B1 (no) 2018-08-20

Similar Documents

Publication Publication Date Title
PE20120581A1 (es) Derivados lactama lactona como intermediarios en la sintesis de inhibidores de renina
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20060932A1 (es) Derivados de sulfonamidas como moduladores de receptores de glucocorticoides (gr)
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
PE20061084A1 (es) Compuestos derivados de 2-ciano-3-(halo)alcoxi-bencenosulfonamida
PE20130647A1 (es) Indoles
PE20130235A1 (es) Derivados de aminopirimidina como moduladores de la lrrk2
AR061372A1 (es) Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion
AR045455A1 (es) Derivados de pirimidina como inhibidores de dipeptidil peptidasa
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
ES2570756T3 (es) Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
DE602005008402D1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
AR049646A1 (es) Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
CO6180449A2 (es) Quinazolinonas y naftiridinonas que incluyen un grupo n-(bifenil-4-ilmetil-n-(piperidin-4-il)acetamida sustituida, utiles para el tratamiento de aterosclerosis
AR058885A1 (es) Compuestos de piperidina 3,5-sustituidos
AR048643A1 (es) Derivados de indol como moduladores selectivos de los receptores androgenicos (sarms)
AR053342A1 (es) Quinolonas y naftiridonas 7- maino alquilildenil- heterociclicas
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica
AR051392A1 (es) Antagonistas no peptidicos de bradiquinina y composiciones farmaceuticas de los mismos
PE20090548A1 (es) Compuestos aza-biciclohexano como inhibidores de trombina
PE20050473A1 (es) Nuevos derivados de pirimidin-2-amina

Legal Events

Date Code Title Description
FG Grant, registration